Mechanisms of action of glatiramer acetate in the treatment of multiple sclerosis

William Sheremata, Yesica Campos

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter is arranged with three sections. The introduction (. Section 1) includes subsections dealing with the history of experimental allergic encephalomyelitis (EAE) and of the development of copolymer ?1, which led to the development of glatiramer acetate as a pharmacological product. Section 2 introduces glatiramer as an immunomodulator, with two subsections. The first outlines the impact on adaptive immune responses, and the second, the so-called "shift" from Th1 to Th2 helper T cell responses. Section 3 deals with the drug as a neuroprotective agent. The first subsection deals with induction of neurotrophic molecules by glatiramer and the second deals with the drugs impact on the innate immune system; a new focus for research on mechanisms of "switching off" damage by macrophages and microglial cells and "turning on" repair and regeneration of axons and myelin. Figures 1 and 2 show the relationships of the elements of immune function discussed in this chapter.

Original languageEnglish (US)
Title of host publicationMultiple Sclerosis
Subtitle of host publicationA Mechanistic View
PublisherElsevier Inc.
Pages339-363
Number of pages25
ISBN (Electronic)9780128010051
ISBN (Print)9780128007631
DOIs
StatePublished - Jan 1 2016

Keywords

  • Copolymer
  • Mechanisms of disease
  • Multiple sclerosis
  • Myelin basic protein

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Mechanisms of action of glatiramer acetate in the treatment of multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this

    Sheremata, W., & Campos, Y. (2016). Mechanisms of action of glatiramer acetate in the treatment of multiple sclerosis. In Multiple Sclerosis: A Mechanistic View (pp. 339-363). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-800763-1.00014-2